June 16 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX :
* Phase 2A allergic rhinitis clinical trial did not meet its primary endpoints using current nasal formulation
* Was verbally informed by its contract research organisation of top-line outcomes and anticipates receiving final report shortly Source text for Eikon: Further company coverage: PAR.AX